(Q43279004)

18 November 2017

title

A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. (English)

1 reference

18 November 2017

main subject

phase II clinical trial

0 references

author name string

Helen J Mackay

1

1 reference

18 November 2017

Anna Tinker

2

1 reference

18 November 2017

Eric Winquist

3

1 reference

18 November 2017

Gillian Thomas

4

1 reference

18 November 2017

Kenneth Swenerton

5

1 reference

18 November 2017

Amit Oza

6

1 reference

18 November 2017

Joana Sederias

7

1 reference

18 November 2017

Percy Ivy

8

1 reference

18 November 2017

Elizabeth A Eisenhauer

9

1 reference

18 November 2017

language of work or name

English

0 references

publication date

8 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

116

1 reference

18 November 2017

issue

2

1 reference

18 November 2017

page(s)

163-167

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

18 November 2017

1 reference

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Vascular endothelial growth factor and prognosis of cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Bowel perforation after radiotherapy in a patient receiving sorafenib.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

High incidence of fistula formation during bevacizumab treatment in rectal cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.012

10.1016/J.YGYNO.2009.08.012

7 January 2021

Identifiers

DOI

1 reference

18 November 2017

1 reference